Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Acticor Biotech SAS. (11/5/19). "Press Release: Acticor Biotech Partner of the BOOSTER Consortium Dedicated to Management and New Treatments of Stroke in Emergeny Situations". Paris.

Region Region France
Organisations Organisation Acticor Biotech SAS
  Group Acticor Biotech (Group)
  Organisation 2 ANR (French National Research Agency)
  Group France (govt)
Products Product personalised medicine / precision medicine
  Product 2 glenzocimab (ACT017)
Index terms Index term BOOSTER Consortium–Acticor Biotech: glenzocimab, 201911– project partner with ph2 study of glenzocimab in combi with mechanical thrombectomy
  Index term 2 BOOSTER Consortium–France (govt): grant, 201911c– ANR RHU grant €9.9m for personalised management of stroke in emergency situations
Persons Person Avenard, Gilles (Acticor Biotech 201612 CEO)
  Person 2 Loyer, Annie-Florence (NewCap 201504)

Acticor Biotech, a clinical stage biotechnology company dedicated to the acute phase of thrombo-embolic diseases, including stroke, announces its participation to the BOOSTER consortium, dedicated to personalized medicine for the management of stroke in emergency situations.

Led by Professor Mikael Mazighi from Paris University, who is neurologist at Lariboisière Hospital and at the A. de Rothschild Foundation (FOR), the BOOSTER consortium is a winner of the fourth round of University Hospital Research (RHU) projects awarded by the French National Research Agency (ANR). BOOSTER aims to develop a personalized stroke care and to make new drugs and technologies available to patients. Stroke is a major public health priority since it is the 1st cause of disabilities and the 2nd cause of death (1st cause in women). The BOOSTER consortium is endowed with nearly €10 million.

In this context, ACTICOR will participate in a multi-center phase II clinical trial enrolling close to 300 patients with a stroke eligible for a mechanical thrombectomy. This trial will evaluate the efficacy of glenzocimab, currently the only anti-thrombotic in clinical development in acute ischemic stroke with limited hemorrhagic risk, in combination with mechanical thrombectomy.

“The BOOSTER consortium aims to develop personalized approach to stroke care in emergency situations. It brings together medical, research and pharmaceutical industry teams, including Acticor Biotech, which will be directly involved via glenzocimab, its anti-thrombotic drug candidate. A clinical trial enrolling close to 300 patients will evaluate the efficacy and safety of glenzocimab in combination with mechanical thrombectomy. Its high therapeutic potential and low hemorrhagic risk make glenzocimab a promising new therapy for the management of acute ischemic stroke”, commented Prof. Mikael Mazighi.

Gilles Avenard, CEO of ACTICOR, added: “We are delighted to be part of the BOOSTER consortium, which will enable us to validate on a large scale therapeutic innovations and care for stroke. It reflects the robustness of our project and a unique opportunity for ACTICOR to collaborate with teams of excellence, including FOR, one of the leading French neurovascular center.”

The BOOSTER consortium (€9,871,428) led by Prof. Mikael Mazighi is developing new approaches for stroke care in patients at high risk of disabilities and death whose rapid treatment and characterization are crucial for patient survival and sequelae mitigation. It is made up of medical (A. de Rothschild Foundation, Hôpital Lariboisière, Hôpital Foch, Caen university hospital, Lyon university hospital federation), research (Inserm and Hospinnomics) and pharmaceutical industry teams (Stago, Balt, Sensome and Acticor). Assistance Publique-Hôpitaux de Paris acts as the coordinating body. The Booster project was one of the winners in the fourth round of University Hospital Research (RHU) projects awarded by the French national research agency (ANR).

BOOSTER: Brain clOt persOnalized therapeutic Strategies for sTroke Emergent Reperfusion

About glenzocimab, the Drug Candidate of Acticor Biotech

Acticor Biotech is developing glenzocimab (ACT017), a humanized Antibody Fragment (Fab). The drug candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidences for antithrombotic glenzocimab efficacy and safety in GPVI inhibition of have been established both ex vivo and in vivo. The target (i.e. GP VI) is involved in the thrombus growth, without impacting the different phases of the physiological haemostasis. This limits the bleeding risk associated with its inhibition.

Glenzocimab is currently being evaluated in ACTIMIS an international, multi-center clinical trial in combination with the reference treatment in patients with acute ischemic stroke.

About Acticor Biotech

Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to develop glenzocimab, a “first-in-class” drug candidate in the therapy of acute thrombo-embolic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.
For more information, please visit:


Acticor Biotech
Gilles Avenard
Chief Executive Officer

Media – NewCap
Annie-Florence Loyer
+33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59

Record changed: 2024-03-30


Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Acticor Biotech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top